In Vivo - Strategic Analysis For Medtech And Pharma Leaders since 1981
Anticipating 2026 ACC/AHA Guideline Updates That Will Impact The Cardiometabolic Landscape
ACC/AHA guidelines are reshaping US payer policies, expanding coverage and access to breakthrough cardiovascular therapies like SGLT2 and PCSK9 inhibitors. But costs, red tape, and uneven access still stand in the way.
Podcast: How Senti Bio’s Programmable Cell Therapy Tackles AML’s Toxicity Problem
Senti Bio CEO Tim Lu explains how logic-gated CAR-NK therapy SENTI-202 distinguishes cancer from healthy cells in AML, achieving 50% response rates with favorable safety.
Beyond Viagra: How Dicot’s Novel Mechanism Could Reshape The $5bn ED Market
The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.
Accelerated Approvals Perked Up While US FDA Excelled At Being Average In 2025
Accelerated approvals of novel products rebounded in 2025 as drug development adapted to major pathway changes enacted in the FDA Omnibus Reform Act, but pending applications suggest a potentially bigger impact outside oncology in 2026.
Can An AI Drug Discovery Company Sustain Itself Without A Pipeline?
Execs at Biotech Showcase debated business models and platform monetization strategies for AI drug discovery companies, with some arguing they should develop internal pipelines and others advocating for partnership models.
